Shineway Pharmaceutical Group (02877) saw its shares rise more than 4%. At the time of writing, the stock was up 4.55%, trading at HK$10.33, with a turnover of HK$10.32 million. The increase follows news that Shineway's Peach Red Four Substance Decoction Granules (National Medicine Approval No. C20260009) have officially received market approval from the National Medical Products Administration. This makes Shineway the first company in Hebei Province to obtain approval for this product. Since the beginning of this year, Shineway has secured approvals for three classical prescription formulas, continuously enriching its portfolio of traditional Chinese medicine classics and accelerating the transformation of these formulas into clinical applications. The company's total number of approved classical prescriptions has now increased to seven, maintaining its leading position nationwide. Shineway's research and development in classical prescriptions has entered a phase of concentrated output, with its product matrix covering multiple therapeutic areas including respiratory, digestive, cardiovascular, metabolic, and gynecological conditions. Leveraging its advanced modern TCM intelligent manufacturing base, several earlier-approved products have been fully launched to the market, gaining widespread recognition from medical institutions and patients for their proven efficacy and consistent quality.